2025年全球視網膜和玻璃體疾病市場報告

預計未來幾年玻璃體視網膜疾病市場規模將強勁成長。到 2029 年，該市場規模將以 7.9% 的年複合成長率（CAGR）到 63 億美元。預測期內的成長可歸因於老齡化黃斑部病變病變盛行率的上升、糖尿病視網膜病變發生率的上升、再生幹細胞療法投資的增加、眼科疾病醫療支出的增加、對視網膜疾病早期發現意識的增強以及政府的支持措施。在此期間，預計的主要趨勢包括基於人工智慧的視網膜疾病檢測、機器人輔助玻璃體視網膜手術、基於奈米技術的藥物傳輸系統、用於即時眼部監測的智慧隱形眼鏡、超高解析度自適應光學成像以及生物分解性的玻璃體內植入。

糖尿病視網膜病變盛行率的不斷上升預計將在未來幾年推動玻璃體視網膜疾病市場的成長。糖尿病視網膜病變是眼科疾病。隨著糖尿病患者數量的增加，這種疾病也變得越來越普遍，其主要原因是久坐的生活方式和血糖控制不佳，這些都會導致視網膜血管受損。玻璃體視網膜疾病的治療對於控制糖尿病視網膜病變、保護視力以及透過解決玻璃體出血和牽引性視網膜剝離等問題來最大限度地減少視網膜的進一步損害至關重要。例如，澳洲政府機構澳洲健康與福利研究所於2024年10月報告稱，2022-23年期間，篩檢的原住民中，1.8%的人接受了糖尿病視網膜病變治療，年齡標準化治療率為1.3%，而非原住民澳洲人的這一比例為1.5%。因此，糖尿病視網膜病變發生率的上升正在推動玻璃體視網膜疾病市場的擴張。

玻璃體視網膜疾病市場的主要企業正在開發原發性玻璃體視網膜淋巴瘤（一種罕見且原發性的視網膜癌）的先進療法，例如基於胺基甲基葉酸的療法。這些治療方法透過玻璃體內注射化療藥物胺基甲基葉酸來抑制視網膜和玻璃體內的癌細胞，從而提供強化有效的治療。例如，2022年12月，美國生技公司Aldeila Therapeutics宣布已成功與FDA就ADX-2191舉行新藥認證申請前（pre-NDA）會議。該產品是一種新型無防腐劑的胺基甲基葉酸製劑，旨在治療原發性玻璃體視網膜淋巴瘤（PVRL），為這種罕見疾病提供了一種有希望的解決方案。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球玻璃體視網膜疾病PESTEL分析（政治、社會、科技、環境、法律因素、促進因素與限制因素）
• 最終用途產業分析
• 全球玻璃體視網膜疾病市場：成長率分析
• 全球玻璃體視網膜疾病市場表現：規模與成長，2019-2024
• 全球玻璃體視網膜疾病市場預測：規模與成長，2024-2029 年，2034 年
• 全球玻璃體視網膜疾病總目標市場（TAM）

第6章市場區隔

• 全球玻璃體視網膜疾病市場類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
• 視網膜撕裂
• 視網膜剝離
• 糖尿病視網膜病變
• 黃斑部病變
• 黃斑裂孔
• 其他類型
• 全球玻璃體視網膜疾病市場（依診斷、表現及預測），2019-2024 年、2024-2029 年、2034 年
• 數位螢光造影
• 光學同調斷層掃描
• 海德堡視網膜斷層掃描
• 靛氰綠造影螢光
• 其他診斷
• 全球玻璃體視網膜疾病市場（依治療、表現及預測），2019-2024 年、2024-2029 年、2034 年
• 外科手術
• 藥品
• 其他治療方法
• 全球玻璃體視網膜疾病市場：依通路、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 醫院藥房
• 網路藥局
• 零售藥局
• 全球玻璃體視網膜疾病市場：按最終用戶、業績和預測，2019-2024 年、2024-2029 年、2034 年
• 醫院
• 居家護理
• 專科診所
• 其他最終用戶
• 全球視網膜及玻璃體疾病市場按視網膜裂孔類型細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 萎縮性視網膜裂孔
• 視網膜撕裂
• 馬蹄形視網膜裂孔
• 巨大視網膜裂孔
• 全球視網膜玻璃體疾病市場，依視網膜剝離類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 孔源性視網膜剝離
• 牽引性視網膜剝離
• 滲出性視網膜剝離
• 全球玻璃體視網膜疾病市場，依糖尿病視網膜病變類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 非增生性糖尿病視網膜病變
• 增生性糖尿病視網膜病變
• 糖尿病黃斑部水腫
• 全球玻璃體視網膜疾病市場按黃斑部病變類型細分、表現和預測，2019-2024 年、2024-2029 年、2034 年
• 乾性黃斑部病變
• 濕性黃斑部病變
• 全球玻璃體視網膜疾病市場黃斑裂孔細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 全層黃斑裂孔
• 板層黃斑裂孔
• 牽引性黃斑裂孔
• 全球視網膜和玻璃體疾病市場，按類型細分，實際和預測，2019-2024 年、2024-2029 年、2034 年
• 視網膜前膜
• 視網膜靜脈阻塞
• 視網膜動脈阻塞
• 視網膜色素變性
• 葡萄膜炎
• 玻璃體積血
• 黃斑部水腫
• 中心性漿液性視網膜病變
• 增生性玻璃體視網膜病變

第7章 區域和國家分析

• 全球玻璃體視網膜疾病市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
• 全球玻璃體視網膜疾病市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

• 視網膜與玻璃體疾病市場：競爭格局
• 視網膜和玻璃體疾病市場：公司簡介
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• Bayer AG
• Novartis AG
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Baxter International
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co. Ltd.
• Topcon Corporation
• Ocular Therapeutix Inc.
• Carl Zeiss Meditec AG
• EyePoint Pharmaceuticals Inc.
• Kodiak Sciences Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029年視網膜和玻璃體疾病市場：提供新機會的國家
• 2029年玻璃體視網膜疾病市場：細分領域帶來新機會
• 2029年視網膜與玻璃體疾病市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第36章 附錄

Vitreoretinal disorder encompasses a group of eye conditions that impact the retina and the vitreous humor, both of which are essential for preserving the eye's shape and ensuring visual clarity. These conditions can lead to progressive vision impairment and often require advanced diagnostic tools and specialized medical or surgical treatments for proper management.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of vitreoretinal disorders include retinal tears, retinal detachment, diabetic retinopathy, macular degeneration, macular holes, and others. A retinal tear is a small break or hole in the retina, the light-sensitive layer at the back of the eye. Diagnosis involves various techniques such as digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, among others. Treatment options include surgery, medication, and additional approaches. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and serve a range of end users including hospitals, home care settings, specialty clinics, and others.

The vitreoretinal disorder market research report is one of a series of new reports from The Business Research Company that provides vitreoretinal disorder market statistics, including vitreoretinal disorder industry global market size, regional shares, competitors with a vitreoretinal disorder market share, detailed vitreoretinal disorder market segments, market trends and opportunities, and any further data you may need to thrive in the vitreoretinal disorder industry. This vitreoretinal disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vitreoretinal disorder market size has grown strongly in recent years. It will grow from$4.30 billion in 2024 to $4.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of diabetic retinopathy, an aging population, increased awareness of retinal diseases, the expansion of healthcare infrastructure, and the early adoption of anti-vascular endothelial growth factor (VEGF) therapy.

The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to$6.30 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The projected growth in the forecast period can be attributed to the rising prevalence of age-related macular degeneration, an increasing incidence of diabetic retinopathy, growing investment in regenerative stem cell therapies, higher healthcare spending on eye diseases, greater awareness of early retinal disease detection, and supportive government initiatives. Key trends expected during this period include AI-powered retinal disease detection, robotic-assisted vitreoretinal surgeries, nanotechnology-based drug delivery systems, smart contact lenses for real-time eye monitoring, ultra-high-resolution adaptive optics imaging, and biodegradable intravitreal implants.

The increasing prevalence of diabetic retinopathy is expected to drive the growth of the vitreoretinal disorder market in the years ahead. Diabetic retinopathy is an eye disease resulting from damage to the retinal blood vessels caused by prolonged high blood sugar levels in individuals with diabetes. This condition is becoming more common due to the growing number of diabetes cases, largely fueled by sedentary lifestyles and inadequate blood sugar control, which lead to retinal vascular damage. Vitreoretinal disorder treatment is essential for managing diabetic retinopathy by addressing issues such as vitreous hemorrhage and tractional retinal detachment, thus helping to preserve vision and minimize further retinal harm. For example, in October 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that during 2022-23, 1.8% of screened First Nations individuals received treatment for diabetic retinopathy, with an age-standardized treatment rate of 1.3%, compared to 1.5% for non-Indigenous Australians. Therefore, the increasing incidence of diabetic retinopathy is contributing to the expansion of the vitreoretinal disorder market.

Leading companies in the vitreoretinal disorder market are developing advanced therapies, such as methotrexate-based treatments, to target primary vitreoretinal lymphoma-a rare and aggressive form of retinal cancer. This approach involves the intravitreal administration of methotrexate, a chemotherapy drug, to suppress cancerous cells in the retina and vitreous, providing a focused and effective treatment. For instance, in December 2022, Aldeyra Therapeutics Inc., a biotechnology company based in the U.S., announced a successful pre-New Drug Application (pre-NDA) meeting with the FDA regarding ADX-2191. This product is a novel, preservative-free methotrexate formulation designed to treat primary vitreoretinal lymphoma (PVRL), offering a promising solution for this rare condition.

In July 2024, Merck & Co. Inc., a U.S.-based pharmaceutical giant, acquired Eyebiotech Limited (EyeBio) for $3 billion. This strategic move aims to expand Merck's portfolio in the field of ophthalmology by adding Restoret (EYE103), a promising therapy for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Eyebiotech Limited, headquartered in the UK, is a clinical-stage biotech firm focused on developing treatments for retinal disorders, including vitreoretinal diseases.

Major players in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., and Clearside Biomedical.

North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in vitreoretinal disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vitreoretinal disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vitreoretinal disorder market includes revenues earned by entities by providing services such as diagnostic services, intravitreal injection therapies, imaging services, teleophthalmology consultations, postoperative care, and retinal rehabilitation services. The vitreoretinal disorder market also includes sales of fundus cameras, injections, and steroid implants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vitreoretinal Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vitreoretinal disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vitreoretinal disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vitreoretinal disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Retinal Tear; Retinal Detachment; Diabetic Retinopathy; Macular Degeneration; Macular Hole; Other Types
• 2) By Diagnosis: Digital Fluorescein Angiography; Optical Coherence Tomography; Heidelberg Retinal Tomography; Indocyanine Green Angiography; Other Diagnosis
• 3) By Treatment: Surgery; Medication; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Retinal Tear: Atrophic Retinal Tear; Operculated Retinal Tear; Horseshoe Retinal Tear; Giant Retinal Tear
• 2) By Retinal Detachment: Rhegmatogenous Retinal Detachment; Tractional Retinal Detachment; Exudative Retinal Detachment
• 3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy; Diabetic Macular Edema
• 4) By Macular Degeneration: Dry Macular Degeneration; Wet Macular Degeneration
• 5) By Macular Hole: Full-Thickness Macular Hole; Lamellar Macular Hole; Tractional Macular Hole
• 6) By Other Types: Epiretinal Membrane; Retinal Vein Occlusion; Retinal Artery Occlusion; Retinitis Pigmentosa; Uveitis; Vitreous Hemorrhage; Macular Edema; Central Serous Retinopathy; Proliferative Vitreoretinopathy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vitreoretinal Disorder Market Characteristics

3. Vitreoretinal Disorder Market Trends And Strategies

4. Vitreoretinal Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vitreoretinal Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vitreoretinal Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vitreoretinal Disorder Market Growth Rate Analysis
• 5.4. Global Vitreoretinal Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vitreoretinal Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vitreoretinal Disorder Total Addressable Market (TAM)

6. Vitreoretinal Disorder Market Segmentation

• 6.1. Global Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retinal Tear
• Retinal Detachment
• Diabetic Retinopathy
• Macular Degeneration
• Macular Hole
• Other Types
• 6.2. Global Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Digital Fluorescein Angiography
• Optical Coherence Tomography
• Heidelberg Retinal Tomography
• Indocyanine Green Angiography
• Other Diagnosis
• 6.3. Global Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Medication
• Other Treatments
• 6.4. Global Vitreoretinal Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Vitreoretinal Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Tear, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atrophic Retinal Tear
• Operculated Retinal Tear
• Horseshoe Retinal Tear
• Giant Retinal Tear
• 6.7. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Detachment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rhegmatogenous Retinal Detachment
• Tractional Retinal Detachment
• Exudative Retinal Detachment
• 6.8. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Diabetic Retinopathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema
• 6.9. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Macular Degeneration
• Wet Macular Degeneration
• 6.10. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Hole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Full-Thickness Macular Hole
• Lamellar Macular Hole
• Tractional Macular Hole
• 6.11. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epiretinal Membrane
• Retinal Vein Occlusion
• Retinal Artery Occlusion
• Retinitis Pigmentosa
• Uveitis
• Vitreous Hemorrhage
• Macular Edema
• Central Serous Retinopathy
• Proliferative Vitreoretinopathy

7. Vitreoretinal Disorder Market Regional And Country Analysis

• 7.1. Global Vitreoretinal Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vitreoretinal Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vitreoretinal Disorder Market

• 8.1. Asia-Pacific Vitreoretinal Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vitreoretinal Disorder Market

• 9.1. China Vitreoretinal Disorder Market Overview
• 9.2. China Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vitreoretinal Disorder Market

• 10.1. India Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vitreoretinal Disorder Market

• 11.1. Japan Vitreoretinal Disorder Market Overview
• 11.2. Japan Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vitreoretinal Disorder Market

• 12.1. Australia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vitreoretinal Disorder Market

• 13.1. Indonesia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vitreoretinal Disorder Market

• 14.1. South Korea Vitreoretinal Disorder Market Overview
• 14.2. South Korea Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vitreoretinal Disorder Market

• 15.1. Western Europe Vitreoretinal Disorder Market Overview
• 15.2. Western Europe Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vitreoretinal Disorder Market

• 16.1. UK Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vitreoretinal Disorder Market

• 17.1. Germany Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vitreoretinal Disorder Market

• 18.1. France Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vitreoretinal Disorder Market

• 19.1. Italy Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vitreoretinal Disorder Market

• 20.1. Spain Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vitreoretinal Disorder Market

• 21.1. Eastern Europe Vitreoretinal Disorder Market Overview
• 21.2. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vitreoretinal Disorder Market

• 22.1. Russia Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vitreoretinal Disorder Market

• 23.1. North America Vitreoretinal Disorder Market Overview
• 23.2. North America Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vitreoretinal Disorder Market

• 24.1. USA Vitreoretinal Disorder Market Overview
• 24.2. USA Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vitreoretinal Disorder Market

• 25.1. Canada Vitreoretinal Disorder Market Overview
• 25.2. Canada Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vitreoretinal Disorder Market

• 26.1. South America Vitreoretinal Disorder Market Overview
• 26.2. South America Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vitreoretinal Disorder Market

• 27.1. Brazil Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vitreoretinal Disorder Market

• 28.1. Middle East Vitreoretinal Disorder Market Overview
• 28.2. Middle East Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vitreoretinal Disorder Market

• 29.1. Africa Vitreoretinal Disorder Market Overview
• 29.2. Africa Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vitreoretinal Disorder Market Competitive Landscape And Company Profiles

• 30.1. Vitreoretinal Disorder Market Competitive Landscape
• 30.2. Vitreoretinal Disorder Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Vitreoretinal Disorder Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Baxter International
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Alcon Inc.
• 31.9. Bausch Health Companies Inc.
• 31.10. Santen Pharmaceutical Co. Ltd.
• 31.11. Topcon Corporation
• 31.12. Ocular Therapeutix Inc.
• 31.13. Carl Zeiss Meditec AG
• 31.14. EyePoint Pharmaceuticals Inc.
• 31.15. Kodiak Sciences Inc.

32. Global Vitreoretinal Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vitreoretinal Disorder Market

34. Recent Developments In The Vitreoretinal Disorder Market

35. Vitreoretinal Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Vitreoretinal Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vitreoretinal Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vitreoretinal Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35026_Vitreoretinal_Disorder_GMR_2025